A sensitive and selective high-performance liquid chromatographic method for the determination of FCE 24928 (4-amino-androsta-1,4,6-triene-3,17-dione) in human plasma is reported. The drug was extracted from buffered (pH = 8) plasma samples with methylene chloride-isooctane, then analysed by reversed-phase liquid chromatography. Quantitation was achieved by ultraviolet detection of the eluate at 238 nm. Blank plasma samples from humans, dog and rat assayed as described showed no significant peak at the retention time of the compound of interest. The suitability of the method for in vivo samples was tested by measuring the plasma levels of FCE 24928 in rats that received oral doses of the test compound.